Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2021-06-01 Report Publication Anno…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document text announces two key events: 1) A conference call presentation for the 2020-2021 annual financial results scheduled for June 16, 2021. This points towards an Earnings Release (ER) or a related event. 2) A change in the date of the Annual General Meeting (AGM) from September 10, 2021, to September 9, 2021. Since the document is primarily an announcement about the timing and details of the financial results presentation (which often accompanies an ER) and a change in the AGM date, it functions as a general corporate announcement regarding upcoming investor events. Given the short length (2476 chars) and the focus on announcing the date/details of the results presentation and the AGM date change, it fits best as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). However, because it explicitly details the schedule for the presentation of the annual results and mentions the AGM date change, it is announcing the publication/discussion of reports and meetings. The most specific fit among the options for an announcement detailing the schedule for discussing annual results and updating the AGM date is RPA, as it is announcing the publication/discussion of financial results and AGM details.
2021-06-01 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of April 30, 2021. This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Since it is a monthly update on the total number of shares and voting rights, it most closely aligns with a notification regarding capital structure changes or significant share ownership thresholds. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in the number of shares, and 'Major Shareholding Notification' (MRQ) covers changes in ownership thresholds. However, this specific report is a mandatory disclosure of the *total* capital structure and voting rights, which is a fundamental component of capital reporting. In many contexts, this specific monthly disclosure is categorized under capital structure updates. Since it is a formal, periodic regulatory filing detailing the capital structure, SHA is a strong fit, but MRQ specifically deals with notifications related to crossing ownership thresholds based on these totals. Given the content is a direct report of the total share count and voting rights, it is a core capital structure disclosure. If a more specific code for 'Total Voting Rights Disclosure' existed, it would be preferred. Between the available options, 'Major Shareholding Notification' (MRQ) is often used for filings that track ownership levels based on these totals, or 'Share Issue/Capital Change' (SHA) for the underlying capital structure data. Since this is a routine monthly report on the *total* capital and voting rights, it is a fundamental capital structure disclosure. I will classify it as SHA as it directly reports the components of the share capital, although it is also related to MRQ thresholds. Given the French context and the nature of the disclosure (capital structure update), SHA is the most appropriate fit among the choices for a document detailing the total number of shares and voting rights.
2021-05-10 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 19, 2021, announcing positive results from a clinical trial regarding the safety (innocuité) of Ivermectin administration. It details study parameters, quotes management, and discusses future development programs (mdc-TTG for Covid-19). This type of announcement, focusing on clinical trial results and strategic updates outside of mandatory periodic financial filings (like 10-K or IR), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, as a Regulatory Filing (RNS) if it's a specific operational/clinical update that doesn't fit other categories. Since it is a specific announcement of clinical trial results and strategic progress, and not a full financial report (10-K, IR) or a transcript (CT), it best fits the general 'Regulatory Filings' (RNS) category as a significant operational update, or potentially 'ER' if interpreted broadly as a major operational milestone announcement. Given the focus on clinical safety data and future product pipeline rather than quarterly earnings figures, RNS is the most appropriate fallback for a specific, non-standard announcement. However, in many contexts, major clinical trial updates that drive investor interest are often grouped with Earnings Releases (ER) or Investor Presentations (IP). Since it is a formal press release announcing a key milestone, and not a presentation (IP) or a general regulatory filing (RNS), and it is not a full financial report, I will classify it as an Earnings Release (ER) as it serves to update the market on a critical operational/development milestone, similar to how companies often release key trial data alongside or instead of quarterly results when significant. Given the options, ER is often used for major operational news releases.
2021-04-19 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 19, 2021, announcing positive safety results from a clinical trial concerning the continuous administration of ivermectin. It details study parameters, quotes management regarding future strategy (mdc-TTG for Covid-19), and provides contact information. This content structure—a formal announcement of scientific/clinical progress and business outlook—is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a more specific financial filing category like 10-K or IR. Since it is an initial announcement of key results (clinical trial safety validation) rather than a comprehensive quarterly report (IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often include operational and clinical milestones alongside financial context, or Regulatory Filing (RNS) if it's purely operational news. Given the focus on trial results and strategic outlook, ER is a strong fit for a non-financial results announcement, but since it is not explicitly reporting quarterly/periodical financial results (key highlights only), and is instead a scientific/operational update, it fits best under the general Regulatory Filings (RNS) category as a significant operational announcement that is not covered by other specific codes (like LTR for legal, or DIV for dividends). However, in many databases, significant operational/clinical updates released via press release are often categorized as ER if they are time-sensitive announcements, or RNS as a general regulatory disclosure. Given the context of a clinical trial validation, which is a major operational milestone, and the lack of explicit financial period reporting, RNS is the safest fallback for a significant, non-standard announcement.
2021-04-19 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total gross and net voting rights as of March 31, 2021. This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure changes or major shareholdings. While it touches upon share capital, it is primarily a disclosure of voting rights count. This fits best under the category for notification of changes in significant share ownership levels or capital structure updates. Given the focus on the total number of voting rights and shares, it is most closely related to 'Major Shareholding Notification' (MRQ) or 'Share Issue/Capital Change' (SHA). However, since it is a mandatory monthly disclosure of the total voting rights base, which is crucial for tracking ownership thresholds, MRQ is a strong candidate. Alternatively, if the system prioritizes capital structure changes, SHA applies. Since the core content is the calculation of voting rights (Total brut/Total net), which is a key component for tracking major shareholdings, MRQ is the most precise fit among the options provided for this specific type of recurring capital/voting rights disclosure, although it is not explicitly a notification *of* a change, but rather a statement of the current total. Given the options, and the fact that it is a specific regulatory disclosure about the capital base used for voting thresholds, I will classify it as a general regulatory filing (RNS) or a capital/share related filing. Since it is a specific, recurring report on the capital structure and voting rights, and not a general announcement of a report (RPA), I will check the definitions again. It is not a 10-K, IR, or ER. It is a specific disclosure about the share capital and voting rights. This type of filing is often categorized under 'Share Issue/Capital Change' (SHA) if it reflects a change, or sometimes under 'Regulatory Filings' (RNS) if it's a mandatory periodic update that doesn't fit elsewhere. Since it provides the total number of shares and voting rights, which is fundamental to capital structure, SHA is plausible. However, in many databases, mandatory periodic voting rights disclosures fall under a general regulatory category if a more specific one isn't available. Given the options, and the fact that it is a specific, recurring regulatory disclosure about the capital base, I will select RNS as the most appropriate fallback for a specific, non-standard report type, or SHA if we interpret 'capital structure changes' broadly. Given the explicit mention of 'nombre d'actions composant le capital social', SHA is a strong fit. Let's re-evaluate: It's a monthly update on the total capital/voting rights. This is often required when thresholds are crossed, but here it's presented as a routine monthly update. SHA covers 'new share issues, stock splits, or other capital changes'. This document reports the *current state* of the capital base. RNS is the general regulatory fallback. I will lean towards RNS as it is a specific, recurring regulatory disclosure that doesn't perfectly match the definitions for SHA (which implies an *action* like an issue or split) or MRQ (which implies a *notification* of crossing a threshold).
2021-04-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is titled with a company name and a specific update regarding a clinical trial phase ('MedinCell: mdc-CWM clinical phase 3 will start in 2021'). It is dated March 25, 2021, and uses language typical of a press release announcing corporate and clinical development milestones (e.g., 'confirms that late-stage clinical trials...', 'The mdc-CWM program development is led and financed by MedinCell's partner...'). It concludes with contact information for Investor Relations and Media relations, and includes standard forward-looking statement disclaimers. This structure strongly indicates an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on clinical trial progress and financing updates rather than comprehensive financial results (which would suggest ER or IR), and it is not a formal regulatory filing like a 10-K, it best fits the 'Earnings Release' category as the primary vehicle for disseminating timely, material operational news to the market, even if the core topic is R&D progress. Given the context of a time-sensitive announcement of future clinical starts and financing, ER is the most appropriate fit among the provided options for a material, non-financial-statement announcement.
2021-03-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.